Tvardi Therapeutics, Inc. (TVRD) stock
TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.10−0.08 (-6.78%)
Close on Nov 16, 2026Market cap $14.67MP/E –Yield 0.00%
Tvardi Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Tvardi Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $18.01M, down 19.3% year over year. For fiscal 2025 it was $18.01M, down 23.8% from the year before. Over ten years it grew -1.6% a year on average. The highest annual figure on record is $113.82M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.01M | -23.8% |
| FY2024 | Dec 31, 2024 | $23.65M | -78.2% |
| FY2023 | Dec 31, 2023 | $108.51M | +18.1% |
| FY2022 | Dec 31, 2022 | $91.88M | +11.1% |
| FY2021 | Dec 31, 2021 | $82.70M | -23.3% |
| FY2020 | Dec 31, 2020 | $107.85M | -5.2% |
| FY2019 | Dec 31, 2019 | $113.82M | +50.7% |
| FY2018 | Dec 31, 2018 | $75.53M | +55.7% |
| FY2017 | Dec 31, 2017 | $48.52M | -1.5% |
| FY2016 | Dec 31, 2016 | $49.25M | +132.1% |
| FY2015 | Dec 31, 2015 | $21.22M | +40.8% |
| FY2014 | Dec 31, 2014 | $15.07M | +73.5% |
| FY2013 | Dec 31, 2013 | $8.69M | +88.9% |
| FY2012 | Dec 31, 2012 | $4.60M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.00M | -31.1% |
| Q1 FY2026 | Mar 31, 2026 | $4.91M | +57.9% |
| Q4 FY2025 | Dec 31, 2025 | $5.49M | -36.2% |
| Q3 FY2025 | Sep 30, 2025 | $3.60M | -24.9% |
| Q2 FY2025 | Jun 30, 2025 | $5.81M | -11.1% |
| Q1 FY2025 | Mar 31, 2025 | $3.11M | -85.8% |
| Q4 FY2024 | Dec 31, 2024 | $8.60M | -69.7% |
| Q3 FY2024 | Sep 30, 2024 | $4.80M | -81.2% |
| Q2 FY2024 | Jun 30, 2024 | $6.53M | -78.5% |
| Q1 FY2024 | Mar 31, 2024 | $21.96M | -9.7% |
| Q4 FY2023 | Dec 31, 2023 | $28.42M | +9.2% |
| Q3 FY2023 | Sep 30, 2023 | $25.45M | +3.1% |
| Q2 FY2023 | Jun 30, 2023 | $30.31M | +52.3% |
| Q1 FY2023 | Mar 31, 2023 | $24.33M | +14.4% |
| Q4 FY2022 | Dec 31, 2022 | $26.01M | +13.9% |
| Q3 FY2022 | Sep 30, 2022 | $24.69M | +59.2% |
| Q2 FY2022 | Jun 30, 2022 | $19.91M | -21.1% |
| Q1 FY2022 | Mar 31, 2022 | $21.27M | +11.2% |
| Q4 FY2021 | Dec 31, 2021 | $22.83M | -15.9% |
| Q3 FY2021 | Sep 30, 2021 | $15.51M | -26.4% |
| Q2 FY2021 | Jun 30, 2021 | $25.23M | -3.4% |
| Q1 FY2021 | Mar 31, 2021 | $19.13M | -43.0% |
| Q4 FY2020 | Dec 31, 2020 | $27.14M | -9.1% |
| Q3 FY2020 | Sep 30, 2020 | $21.07M | -41.5% |
| Q2 FY2020 | Jun 30, 2020 | $26.11M | +7.2% |
| Q1 FY2020 | Mar 31, 2020 | $33.54M | +42.1% |
| Q4 FY2019 | Dec 31, 2019 | $29.86M | +31.0% |
| Q3 FY2019 | Sep 30, 2019 | $35.99M | +61.4% |
| Q2 FY2019 | Jun 30, 2019 | $24.36M | +43.3% |
| Q1 FY2019 | Mar 31, 2019 | $23.61M | +75.8% |
| Q4 FY2018 | Dec 31, 2018 | $22.80M | +97.0% |
| Q3 FY2018 | Sep 30, 2018 | $22.30M | +143.7% |
| Q2 FY2018 | Jun 30, 2018 | $17.00M | +144.2% |
| Q1 FY2018 | Mar 31, 2018 | $13.43M | -35.6% |
| Q4 FY2017 | Dec 31, 2017 | $11.58M | -42.9% |
| Q3 FY2017 | Sep 30, 2017 | $9.15M | -5.4% |
| Q2 FY2017 | Jun 30, 2017 | $6.96M | – |
| Q1 FY2017 | Mar 31, 2017 | $20.84M | – |
| Q4 FY2016 | Dec 31, 2016 | $20.28M | – |
| Q3 FY2016 | Sep 30, 2016 | $9.67M | – |
See a number that looks wrong?